Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
Academic source · New England Journal of Medicine
Source published: · Event / reporting date: 2025-05-31
Site published: 2026-11-04 · Updated: 2026-11-04
This source is linked automatically. Choose a question to get started.
What the paper reports
In the randomized phase 3 VERITAC-2 trial, vepdegestrant improved progression-free survival versus fulvestrant in the ESR1-mutated subgroup, but not significantly in the overall population. The trial enrolled 624 patients with previously treated ER-positive, HER2-negative advanced breast cancer. Grade 3 or higher adverse events occurred more often with vepdegestrant.
Why this paper is included
Illustrates clinical validation of a PROTAC while showing why biomarker-defined outcomes and safety must be read alongside overall results.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections